Other
Relapsed/refractory AML
0
Pipeline Programs↗
15
Active Trials↗
11
Companies Involved↗
Relapsed/Refractory AML is an early-stage landscape with 0 programs across 11 companies. The most active players are Ryvu Therapeutics SA, Sumitomo Pharma America, Inc., Stelexis BioSciences.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
39
clinical trials
Recruiting10 · 26%
Completed10 · 26%
Terminated6 · 15%
Active, not recruiting3 · 8%
Withdrawn3 · 8%
Unknown status3 · 8%
Other4 · 10%
Clinical Trials
Trial Activity
39 trials
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT06307054·24 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)